2 March 2023

ASX Announcement

ADALTA PRESENTS AT SHARECAFÉ HIDDEN GEMS WEBINAR

MELBOURNE Australia 2 March 2023: AdAlta Limited (ASX:1AD), the clinical stage drug discovery company developing novel therapeutic products from its i-body platform is presenting at the ShareCafe Small Cap "Hidden Gems" Webinar, to be held Friday 3 March 2023 from 12:30pm AEDT/ 9:30am AWST.

In his presentation “Next generation protein therapeutics: doing what antibodies cannot”, CEO and Managing Director, Dr Tim Oldham will provide an updated overview of the Company.

This webinar can be viewed live via Zoom and will provide viewers the opportunity to hear from, and engage with, a range of ASX-listed leading micro/mid cap companies.

To access further details of the event and to register at no cost, please copy and paste the following link into your internet browser:

https://us02web.zoom.us/webinar/register/WN_QHDjGR87S22HWSzdGDBIHA

A copy of the webinar will be made available following the event.

Authorised for lodgement by:

Tim Oldham
CEO and Managing Director
March 2023

Notes to Editors

About AdAlta

AdAlta Limited is a clinical stage drug development company headquartered in Melbourne, Australia. The Company is using its proprietary i-body technology platform to solve challenging drug targeting problems and generate a promising new class of single domain antibody protein therapeutics with the potential to treat some of today’s most challenging medical conditions.

The i-body technology mimics the shape and stability of a unique and versatile antigen binding domain that was discovered initially in sharks and then developed as a human protein. The result is a range of unique proteins capable of interacting with high selectivity, specificity and affinity with previously difficult to access targets such as G-protein coupled receptors (GPCRs) that are implicated in many serious diseases. i-bodies are the first fully human single domain antibody scaffold and the first based on the shark motif to reach clinical trials.

AdAlta has completed Phase I clinical studies for its lead i-body candidate, AD-214, that is being developed for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases for which current therapies are sub-optimal and there is a high unmet medical need. AdAlta has a second target in discovery research, also in the field of fibrosis and inflammation.

AdAlta has completed Phase I clinical studies for its lead i-body candidate, AD-214, that is being developed for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases for which current therapies are sub-optimal and there is a high unmet medical need. AdAlta has a second target in discovery research, also in the field of fibrosis and inflammation.

AdAlta's strategy is to maximise the products developed using its next generation i-body platform by internally discovering and developing selected i-body enabled product candidates against GPCRs implicated in fibrosis, inflammation and cancer and partnering with other biopharmaceutical companies to develop product candidates against other classes of receptor, in other indications, and in other product formats.

Further information can be found at: https://adalta.com.au

For more information, please contact:

Investors

Tim Oldham,
CEO & Managing Director
Tel: +61 403 446 665
E: t.oldham@adalta.com.au

Media

IR Department
Tel: +61 411 117 774
E: jane.lowe@irdepartment.com.au

AdAlta
next generation protein therapeutics

Next generation protein therapeutics: doing what antibodies cannot

Tim Oldham PhD, CEO and Managing Director, AdAlta (ASX:1AD)

Share Cafe, 3 March 2023

AdAlta business and focus

Purpose: to go where antibodies cannot

High-value therapeutic product pipeline by deploying platform where traditional antibodies are ineffective

Discovery business

i-body platform
+
In-house discovery team
=
Multiple high value product candidates

Product development business





Experienced pre-clinical and clinical leaders
+
In-house protein engineering
+
Cost effective Australian location
=
Candidates progressed through development milestones then out-licensed

AdAlta's customer value proposition: high value therapeutics addressing difficult targets for challenging diseases

Antibodies cannot do everything!

AdAlta's i-bodies are a differentiated drug discovery platform for difficult diseases



Fibrosis: degenerative, progressive, fatal

AdAlta's AD-214 could meet a desperate need for new approaches for debilitating diseases of the lung (US$3b), kidney (US$10b) and eye (US$15b)

CAR-T cell therapy providing new hope… for blood cancer patients

AdAlta and Carina's i-CAR-T cells could offer same hope for patients with solid tumours (US$20b by end of decade)

Immuno-oncology drugs revolutionising cancer treatment… for some

AdAlta and GE Healthcare's GZMB i-PET imaging agent could identify responders early (US$6b)

AdAlta's pipeline … so far

Target	Product	Indication (*route*)	Discovery		Non-clinical		Clinical		Partner
			Discovery	Lead optimisation	Preclinical	IND enabling	Phase I	Phase II	
CXCR4	AD-214	Lung fibrosis (*IV/inhaled*)							Available to license
		Kidney fibrosis							Available to license
		Eye fibrosis							Available to license
	TBC	Oncology							GPCR
GZMB	*GZMB-PET*	Cancer imaging							GE Healthcare
GPCR Target X	*TBC*	Fibrosis							Available to co-dev
RANKL	ADR3	Osteoporosis							Available to license
Target A	A-i-CAR-T	Oncology							carina biotech
Target B	B-i-CAR-T	Oncology							carina biotech
Target C	C-i-CAR-T	Oncology							carina biotech
~25 other targets		Various							Proof of concpet

AdAlta
next generation protein therapeutics

Powerful discovery platform: i-bodies

i-bodies allow for high affinity, high specificity binding to targets that are intractable for traditional antibodies

Small Molecules

Avoid off-target issues of small molecules

Antibodies

~10% the size of human antibodies

Enables access to novel targets and efficient payload delivery

i-bodies

Unique binding capabilities drive unique pharmacology

Flexible, modular formats

Current strategic focus



AD-214 program

About | Idiopathic Pulmonary Fibrosis (IPF)

Scaring of the lungs irreversibly reduces lung function

>300,000 people living with IPF; 40,000 people die every year

3.8 years median survival

Two current therapies sell for $3b per year …

… despite limited effectiveness, serious side effects

Other fibrosis market opportunities
- Almost every organ: eye, kidney, heart
- “Long COVID” is a developing issue – further increasing the need for better anti-fibrotic drugs.*
- Re-emergence of silicosis

* PM George, et al, “Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy”, Lancet published online May 15, 2020.

AD-214 efficacy validated in IPF mouse model; safety and target engagement in Phase I

AD-214 inhibited development of lung fibrosis in a mouse model at a wide range of doses and dose intervals[1]



AD-214 was well tolerated in Phase I clinical trials and demonstrated high and durable receptor occupancy[2]



[1] Murigenics_20210208. (Fibrosis induced by bleomycin at day 0; treatment commenced day 8; images from 10 mg/kg AD-214 every 4 days; statistical significance assessed using ANOVA and post-hoc Dunnett's test; ns (not significant) = p >0.05, * = p<0.05, ** = p < 0.01 relative to 21-day bleomycin vehicle; negative control is an i-body that does not bind specifically to CXCR4; error bars are standard error of the mean); test substances administered IV except pirfenidone and nintedanib orally.

[2] Clinical Study Report: Protocol ID: ADA-AD-214-1A : Version 1 Dated 07 October 2022

AdAlta is actively partnering AD-214 while preparing for Phase II

Compelling preclinical data in hand or emerging showing AD-214 improves outcomes in four key indications

Lung

IPF/ILD

>US$3b
82 fibrosis trials in
or entering clinic

Kidney

Lupus nephritis, FSGS

>US$10b
6 fibrosis trials in
or entering clinic

Eye

Wet-AMD, PVR

>US$15b
2 fibrosis trials in
or entering clinic



Cancer

23 different cancers, I/O

>US$1b ea
22 trials of CXCR4 agents in
or entering clinic

Next steps

Planning and preparing for Phase II IV clinical trials (lung or kidney fibrosis) – execution subject to financing

- Complimentary preclinical data
- Manufacturing, toxicology study slots booked
- Clinical strategy finalized mid-2023

Partnering discussions accelerating with strong value proposition

- First in class molecule
- Extensive preclinical package; well tolerated in Phase I
- Up to four indications (US$ billion markets), three formulations
- Phase II ready (IV)

Non-dilutive financing strategy

- Partnering, other non-dilutive options in play
- Investing to address partner FAQs
- Working well with vendors to maintain speed AND flexibility

Sources: GlobalData; www.clinicaltrials.gov (accessed 7 and 17 October 2022)

Pharma companies continue to see value in fibrosis assets: IPF examples

Date	Licensor/target	Licensee/acquirer	Transaction Terms	Clinical Phase
Aug-22	KINIKSA	Genentech A Member of the Roche Group	US$80m Upfront US$620m Milestones	2 (Ready)
Nov-21	BLADE THERAPEUTICS	BIOTECH ACQUISITION COMPANY	US$254m Upfront	2 (Ready)
Nov-21	OncoArendi Therapeutics	Galápagos	€320m Milestones	2 (Ready)
Sep-21	Syndax	Incyte	US$152m Upfront US$602m Milestones	2 (Ready)
Nov-19	Promedior	Roche	US$390m Upfront US$1b Milestones	2
Feb-21	泰德制药 TIDE PHARMACEUTICAL	GRAVITON BIOSCIENCE CORPORATION	US$517.5m Milestones	1
Jul-19	bridgebio	Boehringer Ingelheim	€45m Upfront €1.1b Milestones	1
Oct-22	DJS antibodies	abbvie	US$255m Upfront Contingent Milestones	Pre-clinical (+ platform)

Source: Company press releases

AdAlta
next generation protein therapeutics

Co-developed immuno-oncology discovery programs: i-CAR-T

About CAR-T therapies



CAR-T therapies are providing new hope for cancer patients

Therapy involves re-engineering patient's own immune cells so they "see" cancer as a pathogen

6 FDA-approved CAR-T therapies since 2017 … but so far only for blood cancers

>$US1 billion earned in 2020

$US20.3 billion[1] forecast for 2028

Solid tumours to account for >50% of CAR-T revenues by 2030[2]

1. Grandview Research, "T-cell Therapy Market Size, Share & Trends Analysis" Feb 2021 2. Polaris Market Research, "CAR-T Cell Therapy Market Share, Size Trends, Industry Analysis Report", June 2021

i-CAR-T assets: Carina co-development collaboration status

AdAlta and Carina are combining i-bodies and a world class CAR-T platform to create i-CAR-Ts that could offer improved precision, performance and persistence

- ✓ i-body enabled CAR-T (i-CAR-T) cells have successfully demonstrated *in vitro* cancer cell line killing (lysis)[1]
- ✓ Target A: 9 A-i-CAR-T cells screened *in vitro* against cancer cell lines, 3 to progress to more extensive *in vitro* screens and *in vivo* proof of concept H1 2023
- ✓ Next two targets (targets B and C) to commence i-body discovery in Q2 2023



Significant industry interest (from potential additional partners) in using i-bodies for targeting CAR cells

1. ASX release 29 November 2021

i-CAR-T: Valuable cell therapy partnering potential at pre-clinical proof of concept

Date	Licensee	Licensor	No. of assets	Upfront payment (US$m)	Deal Value (US$m)	Upfront/target (US$m)	Deal value/target (US$m)
Jun-22	Bristol Myers Squibb	immatics	2	60	1460	30	730
Jul-20	SANOFI	Kiadis pharma	1	20	988	20	988
Feb-20	GSK	immatics	2	50	600	25	300
Nov-19	Allogene	Notch THERAPEUTICS	1	10	304	10	304
Oct-18	Roche	SQZBIOTECH	1	45	1702	45	1702
Median value				**45**	**988**	**25**	**730**

Source: GlobalData, company press releases, AdAlta analysis

The investment opportunity

Strategy and upcoming milestones to create and crystallise value

Strategy	Milestone		Impact
Realise the value of AD-214	Manufacture toxicology material (H1'23)	→	*Ph II enabling, shortest timeline for partners*
	Preclinical lung, kidney, eye data (Q1-H2'23)	→	*Strengthens partner package, Ph II kidney enabling*
	Finalise Phase II strategy, financing (mid'23)	→	***Enables final Ph II preparation below***
	6 month toxicology studies (Q4'23-Q1'24)	→	*Ph II enabling*
	Manufacture Phase II clinical material (H1'24)	→	*Ph II enabling*
	Progress/ accelerate existing partnering discussions (through 2023)	→	***Refines Ph II; potential first major RoI (return on investment)***
Extend i-CAR programs	A-i-CAR-T *in vivo* efficacy studies (H1-H2'23)	→	***Preclinical PoC; opportunity for early RoI***
	Commence discovery on two targets (Q2'23)	→	*Carina pipeline expansion – future value*
	Progress/accelerate existing co-development discussions (through 2023)	→	***Potential non-dilutive financing for future programs***
i-PET program	Lead candidate preclinical efficacy (timing not forecast)	→	*Visibility to product potential, time to royalties*
Invest in platform	i-body2.0 and research excellence program	→	*Maintain competitive advantage*

Investment proposition

i-body platform to create value
Delivering high value therapeutic candidates and products beyond the reach of traditional antibodies

Fibrosis/inflammation
AD-214: Phase II and partnering
>$3b market potential in first indication[1]
Multiple indication expansion opportunities

Discovery set up for 2nd target

Immuno-oncology
2 co-development collaborations (4 programs)

✓ Carina Biotech: $20b CAR-T market[2]

✓ GE Healthcare: $6b PET market[3]

Demonstrated expertise
In house team and technology
Demonstrated product development and commercial partnership capability
Australian location advantage

Substantial growth opportunities
Shareholders supportive of expansion
Potential partnering revenue contributes cash

Steady news flow
Transaction potential provides upside
Attractive current valuation

1. GlobalData, Idiopathic Pulmonary Fibrosis Opportunity Analysis and Forecasts to 2029, November 2020; kidney and eye fibrosis markets are larger 2. 2028 forecast by Grandview Research, "T-cell Therapy Market Size, Share & Trends Analysis" Feb 2021 3. 2027 forecast by Global Industry Analysts, Imaging Agents: Global Market Trajectory and Analytics, April 2021

AdAlta
next generation protein therapeutics

Contact:

Tim Oldham, CEO and Managing Director
enquiries@adalta.com.au
www.adalta.com.au